Avid Bioservices Inc (CDMO)

[nuke661]

entdoc,

I wrote to Chris Keenan asking what was meant by the "disconnect" statement.

Here is my question (edited for privacy):

According to the transcript of the 12-10-12 conference call Mr. King made the following statement:

“All along, of course, the Front-Line data & Pancreatic data have been sort of looming out there and obviously, over time, will mature. As far as the trigger points for those data points, these are event-driven endpoints, and it's good for patients the longer they go out. Having said that, when we do reach what we think is a good solid result from the studies, and we will be in a position to put those out as they become available, and, obviously, there will likely be a disconnect between those 2 particular clinical results.”

I would greatly appreciate it if you could provide me with exactly what type of “disconnect” Mr. King was referring to. I believe this information to be very important to evaluating the information being provided to shareholders.


And here is his response:

Timing of readout from the trials. As these are two different diseases, patients within these groups live different durations following diagnosis.


Chris Keenan | Senior Director, Investor Relations

Peregrine Pharmaceuticals, Inc.
14282 Franklin Avenue - Tustin, CA - 92780
Tel: [phone] | Corporate: | Fax:
[e-mail] | http://www.peregrineinc.com